Date: 2021-8-1	
	ng Xie
Manuscript Title:	A case of complete response to pyrotinib combined with letrozole as first-line treatment of HER2 preast cancer
	f known):ATM-21-3978
related to the conten parties whose interes to transparency and o	sparency, we ask you to disclose all relationships/activities/interests listed below that are to of your manuscript. "Related" means any relation with for-profit or not-for-profit third ts may be affected by the content of the manuscript. Disclosure represents a commitment loes not necessarily indicate a bias. If you are in doubt about whether to list a interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	/ None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	 None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	✓ None	
4	Consulting fees	 None	

		1	T
	lectures, presentations,	/ None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending	/ _None	
	meetings and/or travel		
8	Patents planned, issued or	/ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ _None	
	n other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ _None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	/ None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	The author has no conflicts of i	nterest to declare.	

Date:		
	e:Liping Liu	
	t Title: A case of complete response to pyrotinib combined with letrozole as first-line treatment of HE R-positive breast cancer	₹2-
Manuscri	t number (if known):ATM-21-3978	
	rest of transparency, we ask you to disclose all relationships/activities/interests listed below that are the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third	
parties w to transp	ose interests may be affected by the content of the manuscript. Disclosure represents a commitment rency and does not necessarily indicate a bias. If you are in doubt about whether to list a possible placetivity/interest, it is preferable that you do so.	

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	/ None	
3	Royalties or licenses	/ None	
4	Consulting fees	/ None	

		1	T
	lectures, presentations,	/ None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending	/ _None	
	meetings and/or travel		
8	Patents planned, issued or	/ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ _None	
	n other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ _None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	/ None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	The author has no conflicts of i	nterest to declare.	

Da	te:2021-8-1		
You	ır Name:Can Tiaı	າ	
Ma	nuscript Title:_A case of co	mplete response to pyroti	nib combined with letrozole as first-line treatment of HER2-
pos	sitive/HR-positive breast ca	ncer	
Ma	nuscript number (if known)	:ATM-21-3978	
rela par to	ated to the content of your ties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
to to	the epidemiology of hypertodication, even if that medic	ension, you should declare ation is not mentioned in oport for the work reporte	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	✓ None	ar pranting of the work
ı	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None	
	No time limit for this item.		

Time frame: past 36 months

✓__None

✓__None

_✓__None

Grants or contracts from

in item #1 above).

Royalties or licenses

Consulting fees

3

4

any entity (if not indicated

		T		
5	Payment or honoraria for	✓ None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	✓ None		
U	testimony	V None		
	testimony			
_				
7	Support for attending	/ None		
	meetings and/or travel			
0	Patents planned, issued or	. A. Nama		
8	•	V None		
	pending			
9	Participation on a Data	/ None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	✓ None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	✓ None		
	Cook or occor operations			
12	Descript of a main many	4 31		
12	Receipt of equipment,	v None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	_ _None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
	The author has no conflicts of interest to declare.			

The author has no conflicts of interest to declare.	

Date:2021-8-1
Your Name:Zheyu Hu
Manuscript Title: A case of complete response to pyrotinib combined with letrozole as first-line treatment of
HER2-positive/HR-positive breast cancer
Manuscript number (if known):ATM-21-3978
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

manuscript only.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	v None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	/ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	/ _None	
4	Consulting fees	✓ None	

	Payment or honoraria for	/ None		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	✓ None		
	testimony			
7	Support for attending meetings and/or travel	/ None		
	meetings and/or traver			
8	Patents planned, issued or	✓ None		
	pending			
9	Participation on a Data	/ None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	/ None		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	v None		
12	Receipt of equipment, materials, drugs, medical	_/ None		
	writing, gifts or other services			
13	Other financial or non-	✓ None		
13	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
Γ	The author has no conflicts of i	nterest to declare		
	The section has no continue of interest to deciding			

Da	te:2021-8-1		
Yo	ur Name: Quchang Ou	yang	
Ma	anuscript Title: A case	of complete response to	pyrotinib combined with letrozole as first-line treatment of
	R2-positive/HR-positive bre		
Ma	anuscript number (if known)		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare ation is not mentioned in	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. End in this manuscript without time limit. For all other items,
the	e time frame for disclosure i	s the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
L	All support for the present	/ None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		

Time frame: past 36 months

✓__None

✓__None

None

No time limit for this item.

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

4

any entity (if not indicated

	1	1						
5	Payment or honoraria for	/ None						
	lectures, presentations,							
	speakers bureaus,							
	manuscript writing or							
	educational events							
6	Payment for expert	✓ None						
	testimony							
7	Support for attending	v None						
	meetings and/or travel							
		4						
8	Patents planned, issued or	/ None						
	pending							
9	Participation on a Data	_ _None						
	Safety Monitoring Board or							
	Advisory Board							
10	Leadership or fiduciary role	_ _None						
	in other board, society,							
	committee or advocacy							
	group, paid or unpaid							
11	Stock or stock options	/ None						
12	Receipt of equipment,	/ None						
	materials, drugs, medical							
	writing, gifts or other							
	services							
13	Other financial or non-	/ None						
	financial interests							
•								
Pl	Please summarize the above conflict of interest in the following box:							
_								
	The author has no conflicts of interest to declare.							
1								

The author has no conflicts of interest to declare.						